Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.

Delaby C, Muñoz L, Torres S, Nadal A, Le Bastard N, Lehmann S, Lleó A, Alcolea D.

Clin Chim Acta. 2019 Mar;490:98-101. doi: 10.1016/j.cca.2018.12.021. Epub 2018 Dec 20.

PMID:
30579960
2.

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort.

Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2018;63(1):373-381. doi: 10.3233/JAD-170927.

3.

Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid.

Le Bastard N, De Deyn PP, Engelborghs S.

Clin Chem. 2015 May;61(5):734-43. doi: 10.1373/clinchem.2014.236679. Epub 2015 Apr 13.

4.

Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up.

Niemantsverdriet E, Feyen BF, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2015;45(4):1039-43. doi: 10.3233/JAD-142103.

PMID:
25633672
5.

Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia.

Van der Mussele S, Le Bastard N, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S.

Aging Ment Health. 2015;19(3):247-57. doi: 10.1080/13607863.2014.924900. Epub 2014 Jun 25.

PMID:
24962058
6.

Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.

Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S290-8. doi: 10.1016/j.jalz.2013.10.004. Epub 2014 Jan 15.

PMID:
24439167
7.

Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.

Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;36(4):759-67. doi: 10.3233/JAD-130107.

PMID:
23666174
8.

Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.

Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelborghs S.

J Alzheimers Dis. 2013;35(1):137-46. doi: 10.3233/JAD-122176.

PMID:
23364139
9.

Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease.

Engelborghs S, Sleegers K, Van der Mussele S, Le Bastard N, Brouwers N, Van Broeckhoven C, De Deyn PP.

J Alzheimers Dis. 2013;35(1):67-73. doi: 10.3233/JAD-101305.

PMID:
23334703
10.

Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease.

Van der Mussele S, Bekelaar K, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S.

Int J Geriatr Psychiatry. 2013 Sep;28(9):947-58. doi: 10.1002/gps.3909. Epub 2012 Dec 17.

PMID:
23255479
11.

Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia.

Vermeiren Y, Le Bastard N, Van Hemelrijck A, Drinkenburg WH, Engelborghs S, De Deyn PP.

Alzheimers Dement. 2013 Sep;9(5):488-98. doi: 10.1016/j.jalz.2012.06.010. Epub 2012 Nov 14.

PMID:
23159046
12.

Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.

Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;33(3):807-22. doi: 10.3233/JAD-2012-110029.

PMID:
23034521
13.

The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.

Engelborghs S, Le Bastard N.

J Neurol Sci. 2012 Nov 15;322(1-2):197-9. doi: 10.1016/j.jns.2012.08.003. Epub 2012 Sep 2.

PMID:
22947896
14.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
15.

Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C.

Biomark Med. 2012 Aug;6(4):419-30. doi: 10.2217/bmm.12.46. Review.

PMID:
22917144
16.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
17.

Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults.

Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S.

Int J Geriatr Psychiatry. 2013 Mar;28(3):265-75. doi: 10.1002/gps.3820. Epub 2012 Apr 30.

PMID:
22549770
18.

Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk.

Bettens K, Brouwers N, Engelborghs S, Lambert JC, Rogaeva E, Vandenberghe R, Le Bastard N, Pasquier F, Vermeulen S, Van Dongen J, Mattheijssens M, Peeters K, Mayeux R, St George-Hyslop P, Amouyel P, De Deyn PP, Sleegers K, Van Broeckhoven C.

Mol Neurodegener. 2012 Jan 16;7:3. doi: 10.1186/1750-1326-7-3.

19.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K.

Alzheimers Dement. 2012 Jan;8(1):65-73. doi: 10.1016/j.jalz.2011.07.004. Epub 2011 Nov 2. Review.

PMID:
22047631
20.

Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease.

Vermeiren Y, Le Bastard N, Clark CM, Engelborghs S, De Deyn PP.

Neurochem Res. 2011 Oct;36(10):1858-62. doi: 10.1007/s11064-011-0504-4. Epub 2011 May 20.

PMID:
21597934
21.

Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites.

Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, Pasquier F, Montoya AG, Peeters K, Mattheijssens M, Vandenberghe R, Deyn PP, Cruts M, Amouyel P, Sleegers K, Van Broeckhoven C.

Mol Psychiatry. 2012 Feb;17(2):223-33. doi: 10.1038/mp.2011.24. Epub 2011 Mar 15.

22.

Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories.

Aries MJ, Le Bastard N, Debruyne H, Van Buggenhout M, Nagels G, De Deyn PP, Engelborghs S.

Int J Geriatr Psychiatry. 2010 Nov;25(11):1186-95. doi: 10.1002/gps.2481.

PMID:
20957694
23.

Altered serum glycomics in Alzheimer disease: a potential blood biomarker?

Chen CC, Engelborghs S, Dewaele S, Le Bastard N, Martin JJ, Vanhooren V, Libert C, De Deyn PP.

Rejuvenation Res. 2010 Aug;13(4):439-44. doi: 10.1089/rej.2009.0992.

PMID:
20426627
24.

Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2010;21(1):291-301. doi: 10.3233/JAD-2010-091501.

PMID:
20421698
25.

No correlation between time-linked plasma and CSF Abeta levels.

Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S.

Neurochem Int. 2009 Dec;55(8):820-5. doi: 10.1016/j.neuint.2009.08.006. Epub 2009 Aug 18.

PMID:
19695299
26.

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S.

Neurochem Int. 2009 Sep;55(4):214-8. doi: 10.1016/j.neuint.2009.02.017. Epub 2009 Mar 5.

PMID:
19524111
27.

Added diagnostic value of CSF biomarkers in differential dementia diagnosis.

Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S.

Neurobiol Aging. 2010 Nov;31(11):1867-76. doi: 10.1016/j.neurobiolaging.2008.10.017. Epub 2009 Jan 15.

PMID:
19150153
28.

Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment?

Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP, Engelborghs S.

Int J Geriatr Psychiatry. 2009 Jun;24(6):556-62. doi: 10.1002/gps.2154.

PMID:
19132643
29.

Reversal of head drop after discontinuation of olanzapine in a DLB patient.

Aries MJ, Debruyne H, Engelborghs S, Le Bastard N, Somers N, Gorissen D, Pickut BA, De Deyn PP.

Mov Disord. 2008 Sep 15;23(12):1760-2. doi: 10.1002/mds.22182.

PMID:
18661562
30.

The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia.

Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Mariën P, Somers N, Nagels G, Pickut BA, De Deyn PP.

Neurochem Int. 2008 May;52(6):1052-60. Epub 2007 Nov 4.

PMID:
18093695
31.

LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.

Le Bastard N, Van Buggenhout M, De Leenheir E, Martin JJ, De Deyn PP, Engelborghs S.

J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):923-4; author reply 924-5. No abstract available.

PMID:
17702886

Supplemental Content

Loading ...
Support Center